PHASE 1/2 STUDY OF AP26113 IN PATIENTS (PTS) WITH ADVANCED MALIGNANCIES, INCLUDING ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSIS OF SAFETY AND EFFICACY AT SELECTED PHASE 2 DOSES

被引：2
|
作者：
Rosell, R. [1 ]
Gettinger, S. [2 ]
Bazhenova, L. A. [3 ]
Langer, C. J. [4 ]
Salgia, R. [5 ]
Gold, K. [6 ]
Shaw, A. T. [7 ]
Dorer, D. J. [8 ]
Kerstein, D. [9 ]
Camidge, D. R. [10 ]
机构：
[1] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol ICO Badalona, Med Oncol Serv, Badalona, Spain
[2] Yale Univ, Sch Med Med Oncol, Thorac Oncol Program, New Haven, CT USA
[3] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA
[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[5] Univ Chicago, Med Ctr, Thorac Oncol, Chicago, IL 60637 USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[7] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA
[8] ARIAD Pharmaceut Inc, Biostat, Cambridge, MA 02139 USA
[9] ARIAD Pharmaceut Inc, Clin Res, Cambridge, MA 02139 USA
[10] Univ Colorado, Ctr Canc, Thorac Oncol, Aurora, CO USA
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv050.3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
99O
引用
收藏
页数：1
相关论文
共 50 条
  • [31] eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients
    Horn, Leora
    Wu, Yi-Long
    Reck, Martin
    Wakelee, Heather A.
    Liang, Chris
    Tan, Fenlai
    Harrow, Kimberly
    Oertel, Vance
    Dukart, Gary
    Mok, Tony
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC)
    Solomon, B.
    Bang, Y. J.
    Camidge, D. R.
    Iafrate, A. J.
    Kwak, E. L.
    Maki, R. G.
    Ou, S. I.
    Salgia, R.
    Shaw, A.
    Clark, J.
    EJC SUPPLEMENTS, 2010, 8 (07): : 117 - 117
  • [33] Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK plus ) Non-Small Cell Lung Cancer Patients Treated with Ensartinib
    Wakelee, H.
    Reckamp, K.
    Leal, T.
    Chiappori, A.
    Waqar, S.
    Zeman, K.
    Neal, J.
    Liang, C.
    Harrow, K.
    Holzhausen, A.
    Zhou, J.
    Selvaggi, G.
    Horn, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S566 - S566
  • [34] Intracranial efficacy of brigatinib (BRG) in patients (Pts) With crizotinib (CRZ)-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and baseline CNS metastases
    Ou, S-H. I.
    Tiseo, M.
    Camidge, R.
    Ahn, M-J.
    Huber, R. M.
    Hochmair, M. J.
    Kim, S-W.
    West, H. L.
    Reckamp, K. L.
    Molina, J. R.
    Liu, G.
    Delmonte, A.
    Viteri, S.
    Bearz, A.
    Summers, Y.
    Reichmann, W.
    Kerstein, D.
    Gettinger, S. N.
    Kim, D-W.
    ANNALS OF ONCOLOGY, 2017, 28
  • [35] Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK-Positive Non-small Cell Lung Cancer
    Lu, Shun
    Zhou, Qing
    Liu, Xiaoqing
    Du, Yingying
    Fan, Yun
    Cheng, Ying
    He, Shan
    Zhao, Huadong
    Li, Heyan
    Wu, Yi-Long
    CLINICAL LUNG CANCER, 2024, 25 (07)
  • [36] eXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
    Horn, Leora
    Wu, Yi-Long
    Reck, Martin
    Liang, Chris
    Tan, Fenlai
    Harrow, Kimberly
    Oertel, Vance
    Dukart, Gary
    Mok, Tony
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] EXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
    Horn, L.
    Wu, Y-L.
    Reck, M.
    Liang, C.
    Tan, F.
    Harrow, K.
    Oertel, V.
    Dukart, G.
    Mok, T. S. K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [38] Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
    Vizcarrondo, F. R.
    Patel, S. P.
    Pennell, N. A.
    Pakkala, S.
    West, H.
    Kratzke, R.
    Tarazi, J.
    Wilner, K.
    Polli, A.
    Tan, W.
    Liu, Y.
    Valota, O.
    Piperdi, B.
    Reckamp, K. L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [39] Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer
    Landi, Lorenza
    Cappuzzo, Federico
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (02) : 203 - 214
  • [40] Comparative analyses of overall survival of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who did not receive ALK inhibitors
    Kim, D.
    Lee, J. K.
    Park, H. S.
    Kulig, K.
    Kim, T. M.
    Lee, S.
    Jeon, Y.
    Chung, D. H.
    Heo, D. S.
    Kim, W. H.
    Bang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345